of a solution in a mixture of water-ethanol (95/5) containing diclofenac sodium, an alginate salt, selected from sodium, potassium or ~~aluminium~~ ammonium alginate, sodium bicarbonate and polyoxyethylene sorbitan monostearate is carried out at a temperature between 44-46°C and said solution formed is added to another solution containing calcium chloride.

10. Method for producing enteric microcapsules according to any of the claims 1 to 4, CHARACTERIZED in that they contain diclofenac epolamine with at least 10%, preferably less than 5%, of diclofenac epolamine crystals, and in that the preparation of a solution in water-ethanol (90/10) containing diclofenac epolamine, an alginate salt, selected from sodium, potassium or ammonium alginate, sodium bicarbonate, polyoxyethylene sorbitan monostearate is carried out at a temperature between 44-46°C and said solution formed is added to another solution containing calcium chloride.

11. Method for producing enteric microcapsules according to any of the claims 1 to 10, CHARACTERIZED in that the microcapsules obtained in step D) have no bitter taste and have enough plasticity and stability to prepare pharmaceutical compositions.

12. Oral multiparticled pharmaceutical composition in the form of capsules, powder for suspension in water or chewable tablets CHARACTERIZED in that it comprises 25 to 100 mg of diclofenac or one of the sodium, potassium or epolamine salts thereof in the form of enteric microcapsules produced with a method according to any of the claims 1 to 11.

13. Oral multiparticled pharmaceutical composition in the form of capsules according to claim 12 CHARACTERIZED in that said microcapsules do not release more than 2% of diclofenac or one of the salts thereof and preferably less than 1% in an acidic medium over 2 hours under stirring and release no less than 90% of the active ingredient they contain in 30 minutes at pH 6.8 or higher also under stirring.

14. Oral multiparticled pharmaceutical composition in the form of powder for suspension in water according to claim 12 CHARACTERIZED in that said microcapsules do not release more than 2% of diclofenac or one of the salts thereof, and preferably less than